Abstract: The present invention pertains to peptides comprising 4 to 10 amino acids including X1-Pro, Pro-X2 or X1-Pro-X2, wherein X1 and X2 are independently selected from Lys, Arg, His, Asp, Glu, Asn and Gln, and the other amino acids are independently selected from Gly, Ala, Val, Leu, Ile, Nle, Nva, Pro, Phe, Tyr, Trp, Cys, Met, Ser and Thr. Such peptides, including LVCYPQ, FRPRIMTP, VVYPD and VDPP, are obtainable from porcine bone marrow cell culture, and have immunostimulating and anti-viral properties.

Abstract: The present invention pertains to peptides comprising 4 to 10 amino acids including X1-Pro, Pro-X2 or X1-Pro-X2, wherein X1 and X2 are independently selected from Lys, Arg, His, Asp, Glu, Asn and Gin, and the other amino acids are independently selected from Gly, Ala, Val, Leu, Ile, Nle, Nva, Pro, Phe, Tyr, Trp, Cys, Met, Ser and Thr. Such peptides, including LVCYPQ (SEQ ID NO: 3), FRPRIMTP (SEQ ID NO: 4), VVYPD (SEQ ID NO: 5) and VDPP (SEQ ID NO: 6), are obtainable from porcine bone marrow cell culture, and have immunostimulating and anti-viral properties.

Abstract: A compound for protecting a vertebrate against infection by helminths comprising hyaluronidase covalently coupled to an immunostimulating carrier, in preferred form, the immunostimulating carrier to which the hyaluronidase is covalently coupled comprising a copolymer of ethylenepiperazine N-oxide and N-ethylacetylethylenepiperazinium bromide (hereafter referred to as "SYNPOL"), and a process for protecting a vertebrate against infection by helminths comprising administration to the vertebrate of a therapeutically effective amount of a compound comprising hyaluronidase covalently coupled to an immunostimulating carrier, preferably SYNPOL, in preferred form, the compound being administered to the vertebrate in the form of a vaccine.

Abstract: The hexapeptide Phe--Leu--Gly--Phe--Pro--Thr, which is derived from a myelopeptide, exhibits immunostimulatory activity when administered to a mammal.

Abstract: The present invention relates to immunopharmacology and, more specifically, to a preparation controlling the T-system of immunity and to a method for producing the same.The preparation controlling the T-system of immunity is characterized by its content as the active principle, peptides with a molecular mass of from 1,500 to 6,000 Dalton having absorption maximum in UV-light at 280 and 275 nm and electrophoretic mobility in a polyacrylamide gel relative to bromophenol blue: 0.062-0.102; 0.156-0.236; 0.354-0.374; 0.382-0.422; 0.432-0.472; 0.485-0.545; 0.850-0.930.The method for producing the preparation according to the present invention comprises homogenization of a tissue of thymus gland in a solution of sodium chloride; the homogenizate is kept for 12-16 hours at a temperature of from 2.degree. to 6.degree. C.